The final week of August brought two new FDA approvals for Parkinson’s medications. MYOBLOC (rimabotulinumtoxinB) – a botulinum toxin type B, was indicated for the treatment of chronic sialorrhea, also known as excessive drooling. NOURIANZ(istradefylline), an adenosine A2A antagonist, was indicated as an add-on therapy for the treatment of off time episodes. This class of drugs blocks the brain chemical adenosine and boosts the signaling of dopamine.
It is an exciting time to have more and more treatment options come out of the research pipeline for people living with Parkinson’s. August’s Lunch with Docs® PD covered this topic in detail. Our featured MDS speaker Robert Hauser, MD, MBA of USF provided an excellent rundown and then answered questions from the community about the research behind recently approved and future medications for Parkinson’s.
If you missed the episode live, you can check it out here .
For more information on the two new drugs, follow the links below, and as always, please discuss with your physician.